MMP-9

If you live with ulcerative colitis, inflammation can persist even when your symptoms settle. Stool MMP-9 is being studied as another way to assess that inflammation. Small human studies have linked it to findings on endoscopy, particularly in ulcerative colitis and in inflammation of an internal bowel pouch after surgery.

This is a research-stage marker. Its clinical usefulness beyond established stool markers hasn't been demonstrated, and studies use different extraction procedures and assays. There are no standardized clinical cutpoints or validated targets for treatment.

What the Enzyme Does in Your Gut

MMP-9 needs zinc to break down proteins, including collagen that helps support the gut lining. Neutrophils are white blood cells that gather in inflamed tissue. They and other cells can release MMP-9, which helps explain its association with intestinal inflammation. The amount recovered in stool is not a direct measurement of how much tissue has been damaged.

This test uses ELISA to report MMP-9 concentration in a stool extract in ng/mL. ELISA uses antibodies to detect a protein. It reports protein concentration, without directly measuring the enzyme's activity. Which inactive, active, or protein-bound forms are detected depends on the particular kit; the method name alone doesn't establish that coverage.

Ulcerative Colitis and Pouchitis

In a study of 94 adults, stool MMP-9 was higher in ulcerative colitis and correlated with inflammation seen during endoscopy, blood C-reactive protein, and fecal calprotectin. The healthy volunteers and people with diarrhea-predominant irritable bowel syndrome in that study had very low or undetectable results. That comparison supports further investigation, but it doesn't establish a diagnostic rule for everyone with diarrhea.

A separate study included 138 people with ulcerative colitis, Crohn's disease, or an internal pouch made from the small intestine after colon surgery. Stool MMP-9 tracked clinical, endoscopic, and biopsy findings in ulcerative colitis and pouchitis. Pouchitis is inflammation of that surgically created pouch.

These findings show an association with inflammation present when the sample was collected. They don't establish that a rise predicts your next flare, that a fall confirms healing, or that adding this test to calprotectin improves treatment decisions.

Children With Newly Diagnosed Colitis

A study of 35 children with newly diagnosed ulcerative colitis found higher stool MMP-9 than in healthy children. But the stool concentration was higher with mild endoscopic inflammation than with moderate inflammation. Serum MMP-9 showed a different pattern, with higher values in more severe disease and disease extending to the right colon.

The reason for that difference wasn't established. These findings don't support treating a stool concentration as a simple scale of disease severity.

Crohn's Disease

The findings in Crohn's disease are mixed. The study that included 50 people with Crohn's found no correlation between stool MMP-9 and disease activity. A later study of 54 people with Crohn's did find an association with inflammation and ulcers seen on endoscopy. Both measured stool MMP-9 by ELISA, though their laboratory protocols and reporting differed.

A low stool MMP-9 result therefore cannot reliably exclude active Crohn's disease. Fecal calprotectin has a much larger evidence base for assessing intestinal inflammation.

A separate study followed 58 people with Crohn's disease and few or no symptoms. Higher baseline serum MMP-9 was associated with subsequent relapse over two years. That was a blood measurement. It doesn't establish that this stool test predicts relapse.

Colorectal Cancer and Advanced Polyps

Stool MMP-9 has also been investigated for detecting colorectal cancer. The results below came from individual studies of people referred for colonoscopy, not a pooled estimate or a population screening program.

In the first study, the decision rule for cancer and high-risk precancerous polyps detected only 59% of the high-risk precancerous polyps. Its control group excluded inflammatory bowel disease, so its accuracy estimates don't establish how well the test separates cancer from colitis.

Later stool protein screens, followed by ELISA testing, also identified MMP-9 as a candidate cancer marker. But another study found no significant difference in stool MMP-9 between its control, precancerous polyp, and cancer groups. Performance has not been consistent enough to establish a screening role.

The specimen distinction matters here too. A study of 516 first-degree relatives of people with colorectal cancer measured serum MMP-9. At the same false-positive rate, it detected about 19% of advanced lesions, compared with about 53% for FIT. Those figures describe a blood test and cannot be assigned to stool MMP-9.

Serial Trends

Research hasn't established how much change in stool MMP-9 exceeds ordinary variation or reliably confirms healing. Using the same laboratory reduces differences caused by methods, but a personal baseline doesn't turn the result into a validated monitoring tool. The evidence also doesn't establish a benefit from collecting baseline results while healthy.

When Results Can Be Misleading

• Different causes can overlap: ulcerative colitis, pouchitis, and colorectal cancer have all been associated with higher stool MMP-9. The result cannot identify the cause of inflammation or diagnose cancer.
• Laboratory methods differ: the antibody kit, extraction procedure, and dilution affect the reported concentration. Results expressed per volume of extract and results adjusted for stool weight aren't interchangeable. Even two ELISA results in ng/mL may not be directly comparable.
• Concentration and activity differ: an ELISA result doesn't show how much of the detected protein is actively breaking down tissue. Studies of enzyme activity or an MMP-9 complex measure something different.
• Blood and tissue findings don't establish stool effects: reports that a medication changes MMP-9 in blood or a biopsy cannot be used to predict its effect on this stool result.